logo
Plus   Neg
Share
Email

ARYZTA Q3 Revenue Down 21.5% On Organic Basis

ARYZTA AG (ARZTY.PK) reported that its third-quarter group revenue was 644.2 million euros, down 21.5% on organic basis, as the effects of COVID-19 impacted revenue in the period, particularly in the second half of March and in April. Quarterly group revenue was down 24.0%.

ARYZTA Europe reported an organic revenue decline of 23.6%, comprising a 1.4% price/mix decline and a volume decrease of 22.2%.

ARYZTA North America reported an organic revenue decline of 20.4%, which comprised entirely of volume decline with a flat price/mix. Currency movement was positive by 1.9%.

ARYZTA Rest of World reported an organic revenue decline of 14.3% in the quarter, as a solid price/mix improvement of 3.7% was offset by a volume decline of 18.0%. Currency movement had a negative impact of 8.0%.

The company noted that trading conditions in the month of May have seen some early signs of recovery and are now showing three consecutive weeks of revenue improvement leading to an organic evolution of negative 33% compared to the prior year.

The company said the COVID-19 will have a material impact on Group performance in fiscal year 2020. It cannot yet fully gauge the consequences that will result from the situation as the short and longer-term impact cannot be fully assessed at this point in time.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT